Effect of Therapy with Insulin Glargine (Lantus®) on Glycemic Control in Toddlers, Children, and Adolescents with Diabetes

Diabetes Technology and Therapeutics

Volumn 5, Issue 5, 2003, Pages 801-806

  Hathout, Eba H ^a   Fujishige, Leigh ^a   Geach, Jonathan ^a   Ischandar, Mariam ^a   Maruo, Shinichiro ^a   Mace, John W ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE;

ADOLESCENT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHILD; CHILDHOOD DISEASE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS;

EID: 0242268978     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503322527003     Document Type: Article

References (13)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Ratner R, Hirsch I, Neifing J, Garg S, Mecca T, Wilson C: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643.
3. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 1984;7:188-199.
4. McKeage K, Goa KL: Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-1624.
5. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L: No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet Med 2002;19:490-495.
6. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
7. Pierber T, Eugene-Jolchine I, Derobert E: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-162.
8. Schober E, Schoenle E, Van Dyk J, Wernick-Panten K: Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001;24:2005-2006.
9. Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001;18:619-625.
10. Hathout EH, McClintock T, Sharkey J, Kytsenko D, Hartwick N, Hadley-Scofield M, Torgeson S, Mace JW: Glycemic, auxologic, and seasonal aspects of continuous subcutaneous insulin infusion therapy in children and young adults with type 1 diabetes. Diabetes Technol Ther 2003;5:175-181.
11. Kein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-268.
12. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636.
13. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309.